Rising Cancer Prevalence Drives Growth In The Oncolytic Virus Therapy Market: The Driving Engine Behind Oncolytic Virus Therapy Market Evolution in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Oncolytic Virus Therapy Market Size Growth Forecast: What to Expect by 2025?
In recent times, the market size for oncolytic virus therapy has experienced significant growth. The market, which is projected to climb from $0.19 billion in 2024 to $0.23 billion in 2025, is anticipated to see a compound annual growth rate (CAGR) of 25.4%. Factors contributing to this growth during the historical period include enhanced genetic engineering methods, a deeper comprehension of the tumor microenvironment, clinical triumphs and regulatory approvals, the emergence of immunotherapy in treating cancer, and progress in gene delivery systems.

How Will the Oncolytic Virus Therapy Market Size Evolve and Grow by 2029?
Expectations are high for the oncolytic virus therapy market, with experts predicting substantial expansion in the next few years. Forecasts suggest that by 2029, the market will have grown to $0.55 billion, showcasing a compound annual growth rate (CAGR) of 23.7%. The increase during the forecast period is expected due to various factors, including the development of oncolytic virus platforms, synergistic therapies involving immune checkpoint inhibitors, personalized medicine strategies, the proliferation of clinical trials, supportive regulatory policies and guidelines. Key trends during this growth period will be innovative breakthroughs in delivery systems, progress in synthetic biology, collaborations in the biopharmaceutical sector, advances in virology and immunology, and a heightened focus on pediatric oncology.

View the full report here:
https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

What Drivers Are Propelling the Growth of Oncolytic Virus Therapy Market Forward?
The surge in cancer instances is predicted to fuel the expansion of the oncolytic virus therapy market in the future. Cancer is a collection of diseases marked by the unchecked proliferation and dissemination of abnormal cells in the body. Oncolytic virus therapy could potentially selectively target cancer cells and annihilate them, while also inducing an immune response against the tumor. This offers a two-pronged strategy for effective cancer treatment. For example, the American Cancer Society Inc., a non-profit organization based in the US, anticipates that there will be 609,820 cancer fatalities and 1,958,310 new cancer incidents in the US during 2022. Hence, the escalating frequency of cancer instances is propelling the advancement of the oncolytic virus therapy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Which Emerging Trends Are Transforming the Oncolytic Virus Therapy Market in 2025?
Prominent entities in the oncolytic virus therapy market are focusing their efforts on securing regulatory approvals to hasten the launch of novel cancer therapies. Regulatory approvals encompass the procedure through which health bodies assess and approve medical products including drugs, biologics, and medical devices for market usage. To illustrate, ImmVira, a biotechnology firm based in China, was awarded the Fast Track designation by the FDA in March 2024 for its oncolytic virus treatment, MVR-T3011 IT. This therapy targets recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who have seen their disease progress after undergoing platinum-based chemotherapy and at least one prior round of anti-PD-1/PD-L1 therapy. Such a designation aims to accelerate the development and review process for treatments that address severe conditions with unmet medical requirements.

What Are the Key Segments in the Oncolytic Virus Therapy Market?
The oncolytic virus therapy market covered in this report is segmented -

1) By Therapy Type: HSV-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, NDV (Newcastle Disease Virus), Other Therapy Types
2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses
3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer
4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:
1) By HSV-Based Oncolytic Virus Therapy: Talimogene Laherparepvec (T-VEC), Other HSV-Based Therapies
2) By Adenovirus-Based Oncolytic Virus Therapy: Onyx-015, AdV-5/3-D24, Other Adenovirus-Based Therapies
3) By Reovirus: Reolysin, Other Reovirus Therapies
4) By Poxviruses: JX-594 (OncoVac), Other Poxvirus Therapies
5) By NDV (Newcastle Disease Virus): NDV-Based Therapies, Other NDV Applications
6) By Other Therapy Types: Combination Therapies, Other Emerging Oncolytic Virus Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12391&type=smp

Who Are the Key Players Shaping the Oncolytic Virus Therapy Market's Competitive Landscape?
Major companies operating in the oncolytic virus therapy market include Pfizer Inc., Johnson & Johnson, Sorrento Therapeutics Inc., AbbVie Inc., AstraZeneca plc, Amgen Inc., Boehringer Ingelheim Group, Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Kissei Pharmaceutical Co. Ltd., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Adze Biotechnology, Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Circio Holding ASA, Lokon Pharma AB, Provectus Biopharmaceuticals Inc., Vibalogics

What Geographic Markets Are Powering Growth in the Oncolytic Virus Therapy Market?
North America was the largest region in the oncolytic virus therapy market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12391

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.